Discovery of a novel class of 2-aminopyrimidines as CDK1 and CDK2 inhibitors
Authors:
- Jinho LeeJLJinho Lee
- Kyoung-Hee KimKKKyoung-Hee Kim
- Shinwu JeongSJShinwu Jeong
- 1 July 2011
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (14) , 4203-4205
Abstract
No abstract availableKeywords
Funding Information
- Keimyung University
- Ministry of Education, Science and Technology
This publication has 11 references indexed in Scilit:
- Synthesis and cytotoxic activity of 2-methylimidazo[1,2-a]pyridine- and quinoline-substituted 2-aminopyrimidine derivativesEuropean Journal of Medicinal Chemistry, 2010
- Cell cycle, CDKs and cancer: a changing paradigmNature Reviews Cancer, 2009
- Synthesis and biological evaluation of novel 2,4,5-substituted pyrimidine derivatives for anticancer activityBioorganic & Medicinal Chemistry Letters, 2009
- Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitorsBioorganic & Medicinal Chemistry Letters, 2008
- Progress in the evaluation of CDK inhibitors as anti-tumor agentsDrug Discovery Today, 2008
- The NCI60 human tumour cell line anticancer drug screenNature Reviews Cancer, 2006
- Cyclin-Dependent Kinase Pathways As Targets for Cancer TreatmentJournal of Clinical Oncology, 2006
- CDK Inhibitors: Cell Cycle Arrest Versus ApoptosisCell Cycle, 2002
- Cyclin-Dependent KinasesInitial Approaches to Exploit a Novel Therapeutic TargetPharmacology & Therapeutics, 1999
- Cytostatic activity of phenylacetate and derivatives against tumor cellsBiochemical Pharmacology, 1995